FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123016439> ?p ?o ?g. }

• W2123016439 abstract "To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients.A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, defined as the time from antiretroviral therapy initiation to first treatment modification. Time-dependent events were analysed by the Kaplan-Meier approach and the Cox proportional hazard model.There are 26,000 HIV-infected patients in the ARCA database, of whom 1654 met study inclusion criteria. Six hundred and thirty-nine (38.6%) received efavirenz, 321 (19.4%) received atazanavir/ritonavir and 694 (41.9%) received lopinavir/ritonavir as a first-line regimen. Over a total observation period of 88 months, equivalent to more than 2805 person-years of follow-up, 618 patients underwent treatment modification. Lopinavir/ritonavir, given twice daily, was associated with a higher discontinuation rate than efavirenz- and atazanavir-based regimens [hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.56-2.15, P = 0.001]. Comparing the once-daily regimens, the rate of discontinuation of efavirenz was higher than that of atazanavir/ritonavir (HR 1.39, 95% CI 1.06-1.83, P = 0.016).Significant differences in treatment duration were observed among the three studied regimens. Once-daily regimens exhibited greater durability than the twice-daily regimen. Among the specific regimens examined, tenofovir/emtricitabine plus atazanavir/ritonavir showed the greatest durability." @default.
• W2123016439 created "2016-06-24" @default.
• W2123016439 creator A5002495981 @default.
• W2123016439 creator A5005804102 @default.
• W2123016439 creator A5011093773 @default.
• W2123016439 creator A5014000382 @default.
• W2123016439 creator A5028821098 @default.
• W2123016439 creator A5039613583 @default.
• W2123016439 creator A5041785868 @default.
• W2123016439 creator A5044035449 @default.
• W2123016439 creator A5046931461 @default.
• W2123016439 creator A5048127995 @default.
• W2123016439 creator A5061140872 @default.
• W2123016439 creator A5062222090 @default.
• W2123016439 creator A5085992339 @default.
• W2123016439 creator A5086743021 @default.
• W2123016439 date "2012-08-21" @default.
• W2123016439 modified "2023-10-03" @default.
• W2123016439 title "Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort" @default.
• W2123016439 cites W1889532030 @default.
• W2123016439 cites W1984207232 @default.
• W2123016439 cites W1994049323 @default.
• W2123016439 cites W2022980866 @default.
• W2123016439 cites W2032623485 @default.
• W2123016439 cites W2049969210 @default.
• W2123016439 cites W2074919119 @default.
• W2123016439 cites W2113897202 @default.
• W2123016439 cites W2119433625 @default.
• W2123016439 cites W2134537454 @default.
• W2123016439 cites W2136381344 @default.
• W2123016439 cites W2145125431 @default.
• W2123016439 cites W2151401891 @default.
• W2123016439 cites W2156085525 @default.
• W2123016439 cites W2171236519 @default.
• W2123016439 cites W4240153861 @default.
• W2123016439 doi "https://doi.org/10.1093/jac/dks339" @default.
• W2123016439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22915463" @default.
• W2123016439 hasPublicationYear "2012" @default.
• W2123016439 type Work @default.
• W2123016439 sameAs 2123016439 @default.
• W2123016439 citedByCount "14" @default.
• W2123016439 countsByYear W21230164392013 @default.
• W2123016439 countsByYear W21230164392014 @default.
• W2123016439 countsByYear W21230164392015 @default.
• W2123016439 countsByYear W21230164392016 @default.
• W2123016439 countsByYear W21230164392017 @default.
• W2123016439 crossrefType "journal-article" @default.
• W2123016439 hasAuthorship W2123016439A5002495981 @default.
• W2123016439 hasAuthorship W2123016439A5005804102 @default.
• W2123016439 hasAuthorship W2123016439A5011093773 @default.
• W2123016439 hasAuthorship W2123016439A5014000382 @default.
• W2123016439 hasAuthorship W2123016439A5028821098 @default.
• W2123016439 hasAuthorship W2123016439A5039613583 @default.
• W2123016439 hasAuthorship W2123016439A5041785868 @default.
• W2123016439 hasAuthorship W2123016439A5044035449 @default.
• W2123016439 hasAuthorship W2123016439A5046931461 @default.
• W2123016439 hasAuthorship W2123016439A5048127995 @default.
• W2123016439 hasAuthorship W2123016439A5061140872 @default.
• W2123016439 hasAuthorship W2123016439A5062222090 @default.
• W2123016439 hasAuthorship W2123016439A5085992339 @default.
• W2123016439 hasAuthorship W2123016439A5086743021 @default.
• W2123016439 hasBestOaLocation W21230164391 @default.
• W2123016439 hasConcept C126322002 @default.
• W2123016439 hasConcept C142462285 @default.
• W2123016439 hasConcept C159047783 @default.
• W2123016439 hasConcept C207103383 @default.
• W2123016439 hasConcept C2777182164 @default.
• W2123016439 hasConcept C2778414717 @default.
• W2123016439 hasConcept C2778715236 @default.
• W2123016439 hasConcept C2779298103 @default.
• W2123016439 hasConcept C2779778239 @default.
• W2123016439 hasConcept C2781392899 @default.
• W2123016439 hasConcept C2781413609 @default.
• W2123016439 hasConcept C2781432083 @default.
• W2123016439 hasConcept C2993143319 @default.
• W2123016439 hasConcept C3013748606 @default.
• W2123016439 hasConcept C44249647 @default.
• W2123016439 hasConcept C71924100 @default.
• W2123016439 hasConceptScore W2123016439C126322002 @default.
• W2123016439 hasConceptScore W2123016439C142462285 @default.
• W2123016439 hasConceptScore W2123016439C159047783 @default.
• W2123016439 hasConceptScore W2123016439C207103383 @default.
• W2123016439 hasConceptScore W2123016439C2777182164 @default.
• W2123016439 hasConceptScore W2123016439C2778414717 @default.
• W2123016439 hasConceptScore W2123016439C2778715236 @default.
• W2123016439 hasConceptScore W2123016439C2779298103 @default.
• W2123016439 hasConceptScore W2123016439C2779778239 @default.
• W2123016439 hasConceptScore W2123016439C2781392899 @default.
• W2123016439 hasConceptScore W2123016439C2781413609 @default.
• W2123016439 hasConceptScore W2123016439C2781432083 @default.
• W2123016439 hasConceptScore W2123016439C2993143319 @default.
• W2123016439 hasConceptScore W2123016439C3013748606 @default.
• W2123016439 hasConceptScore W2123016439C44249647 @default.
• W2123016439 hasConceptScore W2123016439C71924100 @default.
• W2123016439 hasLocation W21230164391 @default.
• W2123016439 hasLocation W21230164392 @default.
• W2123016439 hasLocation W21230164393 @default.
• W2123016439 hasOpenAccess W2123016439 @default.
• W2123016439 hasPrimaryLocation W21230164391 @default.
• W2123016439 hasRelatedWork W2043884818 @default.

• next